Comparison 1. Mortality.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Overall mortality	8	1242	Risk Ratio (M‐H, Fixed, 95% CI)	0.90 [0.64, 1.25]
1.1 Glycopeptide empirical	2	247	Risk Ratio (M‐H, Fixed, 95% CI)	0.93 [0.47, 1.84]
1.2 Glycopeptide first modification	2	279	Risk Ratio (M‐H, Fixed, 95% CI)	0.81 [0.36, 1.80]
1.3 Other antiGP empirical	4	716	Risk Ratio (M‐H, Fixed, 95% CI)	0.91 [0.60, 1.40]
2 Overall mortality (adequate allocation concealment)	7	1118	Risk Ratio (M‐H, Fixed, 95% CI)	0.96 [0.66, 1.40]
2.1 Glycopeptide empirical	2	247	Risk Ratio (M‐H, Fixed, 95% CI)	0.93 [0.47, 1.84]
2.2 Glycopeptide first modification	2	279	Risk Ratio (M‐H, Fixed, 95% CI)	0.81 [0.36, 1.80]
2.3 Other antiGP empirical	3	592	Risk Ratio (M‐H, Fixed, 95% CI)	1.06 [0.61, 1.85]
3 Overall mortality (intention to treat)	6	1001	Risk Ratio (M‐H, Fixed, 95% CI)	0.82 [0.57, 1.19]
3.1 Glycopeptide empirical	1	120	Risk Ratio (M‐H, Fixed, 95% CI)	0.78 [0.31, 1.95]
3.2 Glycopeptide first modification	1	165	Risk Ratio (M‐H, Fixed, 95% CI)	0.46 [0.14, 1.47]
3.3 Other antiGP empirical	4	716	Risk Ratio (M‐H, Fixed, 95% CI)	0.91 [0.60, 1.40]
4 Mortality in Gram‐positive infections	5	195	Risk Ratio (M‐H, Fixed, 95% CI)	1.73 [0.58, 5.12]
5 Overall mortality (antiGP not covering Gram‐negatives)	6	728	Risk Ratio (M‐H, Fixed, 95% CI)	0.88 [0.55, 1.39]
5.1 Glycopeptide empirical	2	247	Risk Ratio (M‐H, Fixed, 95% CI)	0.93 [0.47, 1.84]
5.2 Glycopeptide first modification	2	279	Risk Ratio (M‐H, Fixed, 95% CI)	0.81 [0.36, 1.80]
5.3 Other antiGP empirical	2	202	Risk Ratio (M‐H, Fixed, 95% CI)	0.89 [0.34, 2.36]
6 Infection‐related fatality	8	1810	Risk Ratio (M‐H, Fixed, 95% CI)	1.15 [0.76, 1.75]
6.1 Glycopeptide empirical	4	1030	Risk Ratio (M‐H, Fixed, 95% CI)	1.16 [0.62, 2.17]
6.2 Glycopeptide first modification	2	279	Risk Ratio (M‐H, Fixed, 95% CI)	1.97 [0.51, 7.59]
6.3 Other antiGP	2	501	Risk Ratio (M‐H, Fixed, 95% CI)	1.00 [0.54, 1.87]